Blockchain Registration Transaction Record

Helus Pharma Completes Name Change from Cybin Inc.

Helus Pharma Inc. changes legal name from Cybin Inc., effective Oct. 1, 2026. Shares continue trading as HELP on Nasdaq and Cboe Canada. Focus on novel serotonergic agonists.

This name change signals Helus Pharma's evolution from a clinical-stage discovery company to a commercial-ready pharmaceutical firm, potentially accelerating the path to market for its novel serotonergic agonists. With HLP003 in Phase 3 for major depressive disorder and FDA Breakthrough Therapy Designation, the company is positioning itself as a leader in mental health therapeutics. For investors, the rebranding may enhance brand recognition and reflect growing maturity, while patients suffering from depression and anxiety could benefit from a new class of treatments designed to promote neuroplasticity and provide durable improvements. The move also underscores the increasing convergence of psychedelic-inspired science and mainstream pharmaceutical development.